Patents by Inventor Arasteh Ari Azhir

Arasteh Ari Azhir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION
    Publication number: 20150044193
    Abstract: Compositions and methods are provided for treating a disorder characterized by ?-synuclein dysfunction and/or altered lipid metabolism.
    Type: Application
    Filed: June 16, 2014
    Publication date: February 12, 2015
    Inventors: Amy B. Manning-Bog, Birgitt Schüle, J. William Langston, Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • TREATMENT OF MACROPHAGE-RELATED DISORDERS
    Publication number: 20150037320
    Abstract: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.
    Type: Application
    Filed: May 6, 2014
    Publication date: February 5, 2015
    Applicants: Neuraltus Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Michael S. McGrath, Arasteh Ari Azhir
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 8501244
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: August 6, 2013
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
    Publication number: 20130017259
    Abstract: The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 17, 2013
    Applicant: The Parkinson's Institute
    Inventor: Arasteh Ari Azhir
  • Compositions and Methods for Treating Lysosomal Disorders
    Publication number: 20130012539
    Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.
    Type: Application
    Filed: July 17, 2012
    Publication date: January 10, 2013
    Applicants: The Hospital for Sick Children, Neuraltus Pharmaceuticals, Inc.
    Inventors: Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • Compositions and methods for treating lysosomal disorders
    Patent number: 8252789
    Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 28, 2012
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • Chlorite formulations and methods of preparation and use thereof
    Patent number: 8231856
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: July 31, 2012
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • TREATMENT OF MACROPHAGE-RELATED DISORDERS
    Publication number: 20120134929
    Abstract: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.
    Type: Application
    Filed: July 23, 2010
    Publication date: May 31, 2012
    Inventors: Michael S. McGrath, Arasteh Ari Azhir
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION
    Publication number: 20120052053
    Abstract: Compositions and methods are provided for treating a disorder characterized by ?-synuclein dysfunction and/or altered lipid metabolism.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 1, 2012
    Inventors: Amy B. Manning-Bog, Birgitt Schüele, J. William Langston, Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120021069
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120021070
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: September 29, 2011
    Publication date: January 26, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite Formulations and Methods of Preparation and Use Thereof
    Publication number: 20120015051
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Application
    Filed: May 9, 2011
    Publication date: January 19, 2012
    Applicant: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • Chlorite formulations, and methods of preparation and use thereof
    Patent number: 8067035
    Abstract: Described herein are chlorite formulations having a pH between about 7 and about 8.5, wherein the chlorite formulations are substantially free of deleterious non-chlorite components. Described herein are chlorite formulations, including pharmaceutical formulations, which are formulated for systemic, parenteral, or intravenous administration. Described herein are methods of preparing and methods of using the chlorite formulations described herein.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 29, 2011
    Assignee: Neuraltus Pharmaceuticals, Inc.
    Inventors: William Boulanger, Arasteh Ari Azhir
  • COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS
    Publication number: 20090163500
    Abstract: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 25, 2009
    Applicants: The Hospital for Sick Children, Taiji Biomedical, Inc.
    Inventors: Clifford A. Lingwood, Michael S. McGrath, Arasteh Ari Azhir